 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| BLD-2660 / Blade Therap
Trial completion, Trial completion date: Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - Apr 6, 2022
P2, N=120, Completed, Sponsor: Blade Therapeutics
Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Jun 2021
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Small-molecule antiviral agents in ongoing clinical trials for COVID-19. (Pubmed Central) - Jan 6, 2022
These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed.
- | BLD-2660 / Blade Therap
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF (clinicaltrials.gov) - Mar 4, 2021
P2a, N=0, Withdrawn, Sponsor: Blade Therapeutics
The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed. N=32 --> 0 | Trial completion date: May 2021 --> Nov 2020 | Suspended --> Withdrawn | Trial primary completion date: Mar 2021 --> Sep 2020
- | BLD-2660 / Blade Therap
Trial completion date: Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - Feb 22, 2021
P2, N=120, Active, not recruiting, Sponsor: Blade Therapeutics
N=32 --> 0 | Trial completion date: May 2021 --> Nov 2020 | Suspended --> Withdrawn | Trial primary completion date: Mar 2021 --> Sep 2020 Trial completion date: Nov 2020 --> Nov 2021
- | BLD-2660 / Blade Therap
Enrollment change, Trial withdrawal: Healthy Volunteer Study Comparing Tablet and Capsule Formulations (clinicaltrials.gov) - Oct 29, 2020
P1, N=0, Withdrawn, Sponsor: Blade Therapeutics
Trial completion date: Nov 2020 --> Nov 2021 N=34 --> 0 | Not yet recruiting --> Withdrawn
- || BLD-2660 / Blade Therap
Enrollment closed: Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - Oct 29, 2020
P2, N=120, Active, not recruiting, Sponsor: Blade Therapeutics
N=34 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | BLD-2660 / Blade Therap
Trial completion date, Trial primary completion date: Healthy Volunteer Study Comparing Tablet and Capsule Formulations (clinicaltrials.gov) - Sep 2, 2020
P1, N=34, Not yet recruiting, Sponsor: Blade Therapeutics
Recruiting --> Active, not recruiting Trial completion date: Nov 2019 --> Jul 2021 | Trial primary completion date: Oct 2019 --> Jun 2021
- ||| BLD-2660 / Blade Therap
Trial completion date, Trial initiation date, Trial suspension, Trial primary completion date: Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF (clinicaltrials.gov) - Sep 2, 2020
P2a, N=32, Suspended, Sponsor: Blade Therapeutics
Trial completion date: Nov 2019 --> Jul 2021 | Trial primary completion date: Oct 2019 --> Jun 2021 Trial completion date: Dec 2020 --> May 2021 | Initiation date: Apr 2020 --> Nov 2020 | Not yet recruiting --> Suspended | Trial primary completion date: Aug 2020 --> Mar 2021
- ||| BLD-2660 / Blade Therap
Enrollment open: Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - May 7, 2020
P2, N=120, Recruiting, Sponsor: Blade Therapeutics
Trial completion date: Dec 2020 --> May 2021 | Initiation date: Apr 2020 --> Nov 2020 | Not yet recruiting --> Suspended | Trial primary completion date: Aug 2020 --> Mar 2021 Not yet recruiting --> Recruiting
- |||| BLD-2660 / Blade Therap
New P2 trial: Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - Apr 5, 2020
P2, N=120, Not yet recruiting, Sponsor: Blade Therapeutics
- ||| BLD-2660 / Blade Therap
Trial completion: First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis (clinicaltrials.gov) - Mar 18, 2020
P1a/1b, N=88, Completed, Sponsor: Blade Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Completed
- || BLD-2660 / Blade Therap
New P2a trial: Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF (clinicaltrials.gov) - Jan 27, 2020
P2a, N=32, Not yet recruiting, Sponsor: Blade Therapeutics
- || BLD-2660 / Blade Therap
Trial completion date, Trial primary completion date: First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis (clinicaltrials.gov) - Jun 27, 2019
P1a/1b, N=88, Recruiting, Sponsor: Blade Therapeutics
Recruiting --> Completed Trial completion date: May 2019 --> Nov 2019 | Trial primary completion date: Apr 2019 --> Sep 2019
- || BLD-2660 / Blade Therap
New P1 trial: Healthy Volunteer Study Comparing Tablet and Capsule Formulations (clinicaltrials.gov) - Jun 27, 2019
P1, N=34, Not yet recruiting, Sponsor: Blade Therapeutics
- || BLD-2660 / Blade Therap
Trial primary completion date: First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis (clinicaltrials.gov) - Jan 15, 2019
P1a/1b, N=88, Recruiting, Sponsor: Blade Therapeutics
Trial completion date: May 2019 --> Nov 2019 | Trial primary completion date: Apr 2019 --> Sep 2019 Trial primary completion date: Dec 2018 --> Apr 2019
- | BLD-2660 / Blade Therap
New P1 trial: First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis (clinicaltrials.gov) - Jul 15, 2018
P1a/1b, N=88, Recruiting, Sponsor: Blade Therapeutics
- | BLD-2660 / Blade Therap
Enrollment open: First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis (clinicaltrials.gov) - Jun 19, 2018
P1a/1b, N=88, Recruiting, Sponsor: Blade Therapeutics
Trial primary completion date: Dec 2018 --> Apr 2019 Not yet recruiting --> Recruiting